Results 61 to 70 of about 7,371 (204)
Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar +5 more
wiley +1 more source
Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy [PDF]
The pathogenesis of orbital Graves' disease (GD), a process known as thyroid-associated ophthalmopathy (TAO), remains incompletely understood. The thyrotropin receptor (TSHR) represents the central autoantigen involved in GD and has been proposed as the ...
Janssen, J.A.M.J.L. (Joop) +1 more
core +4 more sources
Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset +13 more
wiley +1 more source
Inactive Graves' ophthalmopathy and self-esteem [PDF]
PURPOSE: To assess the self-esteem of Graves' ophthalmopathy patients in the inactive phase. METHODS: Thirty euthyroid patients were evaluated in the inactive phase of disease with age ranging from 26 to 65 years, average of 43 ± 11,0 years, called study
Ferreira, Lydia Masako +5 more
core +2 more sources
TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang +16 more
wiley +1 more source
Hooshang Lahooti, Kishan R Parmar, Jack R WallThe Department of Medicine, University of Sydney, Nepean Clinical School, Penrith, NSW, AustraliaAbstract: Thyroid-associated ophthalmopathy (TAO), or thyroid eye disease, is a complex inflammatory disorder ...
Hooshang Lahooti +2 more
doaj
Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development
Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (Graves' disease), also known as Graves' ophthalmopathy/orbitopathy. As an organ-specific autoimmune disease, the pathogenesis of TAO is still
Yazhuo Huang +3 more
doaj +1 more source
Differential Diagnosis of Thyroid Dermopathy and Acropachy with Arthritis
Thyroid acropachy is a rare manifestation of autoimmune thyroid disease with characteristic imaging findings. Clinically, it is almost always associated with thyroid ophthalmopathy and dermopathy.
Nurdan Yılmaz, Pelin Gümüş Ok
doaj +1 more source
Graves’ ophthalmopathy (GO), also known as thyroid-associated ophthalmopathy, is a common potentially vision-threatening organ-specific autoimmune disease and the most common extrathyroidal manifestation of Graves’ disease.
Jingyi Zheng +8 more
doaj +1 more source
Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy [PDF]
The CXC chemokine receptor (CXCR) 3 and its chemokines (CXCL9, CXCL10, CXCL11) are involved in the pathogenesis of autoimmune disesases. Under the influence of interferon (IFN) γ, the IFNγ-inducible chemokines are secreted by lymphocytes, and by ...
Antonelli, Alessandro +4 more
core +1 more source

